Evidence map›Paper›PMID 34284875›Full record

ArticleVaccine2022

Vaccinating Australia: How long will it take?

Mark Hanly, Timothy Churches, Oisín Fitzgerald, C Raina MacIntyre, Louisa Jorm

Open access · greenAbstract read
In one paragraph

Article in Vaccine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.0field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Mark HanlyCentre for Big Data Research in Health, UNSW Sydney, Australia. Electronic address: m.hanly@unsw.edu.au.
Timothy ChurchesSouth Western Sydney Clinical School, Faculty of Medicine & Health, UNSW Sydney & Ingham Institute for Applied Medical Research, Australia. Electronic address: timothy.churches@unsw.edu.au.
Oisín FitzgeraldCentre for Big Data Research in Health, UNSW Sydney, Australia. Electronic address: o.fitzgerald@unsw.edu.au.
C Raina MacIntyreBiosecurity Research Program, The Kirby Institute UNSW Sydney, Australia. Electronic address: rainam@protonmail.com.
Louisa JormCentre for Big Data Research in Health, UNSW Sydney, Australia. Electronic address: l.jorm@unsw.edu.au.
UNSW Sydney · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The Australian Government began to roll out the national COVID-19 vaccination program in late February 2021, with the initial aim to vaccinate the Australian adult population by the end of October 2021. The task of vaccinating some 20 million people presents considerable logistic challenges, but a rapid rollout is essential to allow for the reopening of borders and is especially urgent as new more transmissible variants arise. Here, we run a series of projections to estimate how long it will take to vaccinate the Australian population under different assumptions about the rate of vaccine administration, the schedule for vaccine eligibility and prevalence of vaccine hesitancy. Our analysis highlights the number of vaccine doses that can be administered per day as the key factor determining the duration of the vaccine rollout. A rate of 200,000 doses per day would achieve 90% population coverage by the end of 2021; 80,000 doses a day would see the rollout extended until mid-2023. Vaccine hesitancy has the potential to greatly slow down the rollout and becomes the main limiting factor when the supply of vaccine doses is high. Speed is of the essence when it comes vaccinating populations against COVID-19: a rapid rollout will minimise the risk of sporadic and costly lockdowns and the potential for small, local clusters getting out of control and sparking new epidemic waves. In order to achieve rapid population coverage, the Australian government must ramp up vaccine administration to at least 200,000 doses per day as quickly as possible, while also promoting vaccine willingness in the community through clear public health messaging, especially to known hesitant demographics.

Indexed as

COVID-19AdultAustraliaCommunicable Disease ControlCOVID-19 VaccinesHumansSARS-CoV-2VaccinationCOVID-19 VaccinesAustraliaCOVID-19Vaccination

Identifiers

PMID34284875
PMCPMC8285754
OpenAlexW3184405787

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.